Stock IRWD IRONWOOD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Ironwood Pharmaceuticals, Inc.

Equities

IRWD

US46333X1081

Delayed Nasdaq
Other stock markets
 03:47:36 2024-05-09 pm EDT 		5-day change 1st Jan Change
6.675 USD -17.80% Intraday chart for Ironwood Pharmaceuticals, Inc. -19.40% -41.52%
07:58pm Sector Update: Health Care Stocks Gain in Thursday Afternoon Trading MT
07:44pm Sector Update: Health Care MT

Evolution of the average Target Price on Ironwood Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

ea1d.g1ZW9R-qx-aCpb0_rVBla10lafFUEEN9iGtxcoYcxfA.1mc5mXfZnpK2lcRb6T5XCWRVIJcldTMl31tJHu8skrG3AyytMtCjoLHDhQ~be37049fa420637926cfa5f5b1f2ca19

Analyst Recommendations on Ironwood Pharmaceuticals, Inc.

Piper Sandler Adjusts Price Target on Ironwood Pharmaceuticals to $21 From $20, Maintains Overweight Rating MT
Craig-Hallum Starts Coverage on Ironwood Pharmaceuticals with Buy Rating, $21 Price Target MT
JMP Securities Starts Ironwood Pharmaceuticals at Market Outperform, $22 Price Target MT
Piper Sandler Adjusts Price Target on Ironwood Pharmaceuticals to $19 From $16, Maintains Overweight Rating MT
Capital One Securities Initiates IRWD at Overweight with $15 Price Target MT
Wells Fargo Adjusts Ironwood Pharmaceuticals' Price Target to $13 from $12, Maintains Equalweight Rating MT
Piper Sandler Starts Ironwood Pharmaceuticals at Overweight With $16 Price Target MT
IRONWOOD PHARMACEUTICALS : Morgan Stanley Adjusts Price Target on Ironwood Pharmaceuticals to $14 From $13, Maintains Equal-Weight Rating MT
IRONWOOD PHARMACEUTICALS : Morgan Stanley Adjusts Price Target on Ironwood Pharmaceuticals to $12 From $11, Maintains Equal-Weight Rating MT
IRONWOOD PHARMACEUTICALS : Morgan Stanley Adjusts Ironwood Pharmaceuticals' Price Target to $12 from $11, Keeps Equalweight Rating MT
IRONWOOD PHARMACEUTICALS : Credit Suisse Adjusts Ironwood Pharmaceuticals' Price Target to $12 From $11, Maintains Neutral Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
8.12 USD
Average target price
17.4 USD
Spread / Average Target
+114.29%
High Price Target
23 USD
Spread / Highest target
+183.25%
Low Price Target
14 USD
Spread / Lowest Target
+72.41%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Ironwood Pharmaceuticals, Inc.

Piper Sandler
Craig-Hallum
JMP Securities
Capital One Securities
Wells Fargo Securities
Morgan Stanley

Ratings for Ironwood Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. IRWD Stock
  4. Consensus Ironwood Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW